NEW YORK, July 16, 2020 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, announced
today that on July 15, 2020, the
compensation committee of Seelos' board of directors approved the
grant of a stock option to purchase 50,000 shares of common stock
to one new employee. The stock option was granted as
inducements material to the new employee entering into employment
with Seelos in accordance with Nasdaq Listing Rule
5635(c)(4).
The stock option has an exercise price equal to $1.01, the closing price per share of Seelos'
common stock, as reported by Nasdaq, on July
15, 2020, the date of grant. The option is a non-qualified
stock option and 1/4th of the shares subject to the option vest on
the one-year anniversary of the grant date and an additional 1/48th
of the shares subject to the option vest monthly thereafter over
the next three years, in each case provided that the new employee
remains continuously employed by Seelos through the applicable
vesting date, inclusive.
Seelos is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Seelos Therapeutics
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and advancement of novel
therapeutics to address unmet medical needs for the benefit of
patients with central nervous system (CNS) disorders and other rare
diseases. The Company's robust portfolio includes several
late-stage clinical assets targeting indications including Acute
Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder
(MDD) or Post-Traumatic Stress Disorder (PTSD), Sanfilippo
syndrome, Parkinson's Disease, other psychiatric and movement
disorders plus orphan diseases.
For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Forward-looking Statements
This press release contains forward-looking statements subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. Forward-looking statements
include statements about the employees and equity plans. Risks and
uncertainties include risks associated with the Company's employees
and equity plans, and additional risks set forth in the Company's
filings with the Securities and Exchange Commission. These
forward-looking statements represent the Company's judgment as of
the date of this release. The Company disclaims, however, any
intent or obligation to update these forward-looking
statements.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl.
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original
content:http://www.prnewswire.com/news-releases/seelos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301095137.html
SOURCE Seelos Therapeutics, Inc.